La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Anavex Life Sciences Gestione
Gestione criteri di controllo 3/4
Anavex Life Sciences' Il CEO è Chris Missling, nominato in Jul2013, e ha un mandato di 11.08 anni. la retribuzione annua totale è $ 3.89M, composta da 18% di stipendio e 82% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.47% delle azioni della società, per un valore di $ 7.61M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 10.3 anni.
Informazioni chiave
Chris Missling
Amministratore delegato
US$3.9m
Compenso totale
| Percentuale dello stipendio del CEO | 18.0% |
| Mandato del CEO | 11.3yrs |
| Proprietà del CEO | 1.5% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 10.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Anavex shares up 65% in morning trading continuing hot streak
Feb 04Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
Compensazione vs Mercato: La retribuzione totale di Chris ($USD 3.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).
Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Chris Missling (58 yo)
11.3yrs
Mandato
US$3,894,453
Compensazione
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 7.1m | |
| Principal Financial Officer & Treasurer | 9yrs | US$501.06k | 0.027% $ 129.7k | |
| Chief Scientific Officer | 2.8yrs | Nessun dato | Nessun dato | |
| VP of Corporate | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Nonclinical Development | 3.4yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 2.8yrs | Nessun dato | Nessun dato | |
| Head of Biostatistics | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Head of Research and Development | less than a year | Nessun dato | Nessun dato |
2.8yrs
Durata media
Gestione esperta: Il team dirigenziale di AVXL è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 7.1m | |
| Independent Chairman | 3.4yrs | US$349.54k | Nessun dato | |
| Member of the Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | 13.7yrs | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | 10.8yrs | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | 10.9yrs | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 7.4m | |
| Member of the Scientific Advisory Board | 10.4yrs | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Independent Director | 9.3yrs | US$341.54k | 0.0059% $ 28.3k | |
| Lead Independent Director | 6.6yrs | US$357.54k | Nessun dato |
10.4yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di AVXL è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).